FLLL32

®

MedChemExpress

Cat. No.:	HY-100544
CAS No.:	1226895-15-3
Molecular Formula:	$C_{28}H_{32}O_{6}$
Molecular Weight:	464.55
Target:	STAT; JAK; Apoptosis
Pathway:	JAK/STAT Signaling; Stem Cell/Wnt; Epigenetics; Protein Tyrosine Kinase/RTK; Apoptosis
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (215.26 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg		
		1 mM	2.1526 mL	10.7631 mL	21.5262 mL		
		5 mM	0.4305 mL	2.1526 mL	4.3052 mL		
		10 mM	0.2153 mL	1.0763 mL	2.1526 mL		
	Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.38 mM); Clear solution						
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.38 mM); Clear solution						
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.38 mM); Clear solution						

BIOLOGICAL ACTIVITY				
Description	FLLL32, a synthetic analog of curcumina, is a JAK2/STAT3 dual inhibitor with anti-tumor activity. FLLL32 can inhibit the induction of STAT3 phosphorylation by IFNα and IL-6 in breast cancer cells ^{[1][2]} .			
IC ₅₀ & Target	JAK2/STAT3 ^[1]			
In Vitro	FLLL32 specifically reduces STAT3 phosphorylation at Tyr705 (pSTAT3) and induces apoptosis at micromolar amounts in human melanoma cell lines and primary melanoma cultures ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			

CUSTOMER VALIDATION

- Cancer Gene Ther. 2021 Aug 27.
- Acta Biochim Biophys Sin. 2021 May 21;53(6):697-706.
- Cancer Manag Res. 2020 Nov 24;12:12067-12075.
- Biochem Biophys Res Commun. 2021 May 22;562:43-49.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Bill MA, et al. The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3inhibition and retains the cellular response to cytokines with anti-tumor activity. Mol Cancer. 2010 Jun 25;9:165.

[2]. Lin L, et al. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreaticand breast cancer cells. Cancer Res. 2010 Mar 15;70(6):2445-54.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA